Pharmaco-métabolomique et métabolomique : un nouvel outil en médecine de précision ? [0.03%]
药物代谢组和代谢组：精准医学的新工具？
Antonin Lamazière,Erwan Werner,Caroline Barau et al.
Antonin Lamazière et al.
Pharmaco-metabolomics and metabolomics: A new tool in precision medicine? [0.03%]
药物代谢组学和代谢组学：精准医疗的新工具吗？
Antonin Lamazière,Erwan Werner,Caroline Barau et al.
Antonin Lamazière et al.
Precision medicine aims to integrate individual patient characteristics into therapeutic decisions. Metabolomics and pharmaco-metabolomics enable direct exploration of the biological phenotype through comprehensive analysis of the metabolit...
Comment discriminer les médicaments d’ASMR V : quelles implications et quel parcours d’accès ? [0.03%]
如何区分药物和ASMR V：有什么影响和访问途径？
Clémentine Body,Frédéric Chassagnol,Driss Berdaï et al.
Clémentine Body et al.
Beyond the hype: The multifaceted reality of artificial intelligence in pharmacology [0.03%]
超越炒作：药理学中人工智能的多面现实
Jean-Baptiste Woillard
Jean-Baptiste Woillard
How can the level of health product education (literacy) be raised among the general public? [0.03%]
如何提高公众对健康产品的认识(普及率)?
Clara Locher,Nathalie Manaud,Mathieu Molimard et al.
Clara Locher et al.
Recognising the pivotal role of health products in our society, the challenges around accessing reliable information in a fast-expanding digital environment, and the essential role played by health literacy in enabling citizens to make info...
Comment améliorer le niveau d’éducation (littératie) de la population sur les produits de santé ? [0.03%]
如何提高人口的医疗产品健康素养水平？
Clara Locher,Nathalie Manaud,Mathieu Molimard et al.
Clara Locher et al.
Medical devices for professional use: What assessment, what funding? [0.03%]
专业用途的医疗设备：进行何种评估？如何提供资金支持？
Valéry-Pierre Riche,Laure de Place,Xavier Armoiry et al.
Valéry-Pierre Riche et al.
Medical devices for professional use professional use medical device (DMUPs) are playing an increasingly important role in healthcare systems, driven by the rise of digital technologies. They encompass a wide range of equipment, from roboti...
How to differentiate between clinical added value (CAV) V drugs: What are the implications, and what is the access pathway? [0.03%]
如何区分临床附加价值(CAV)V类药物：其影响及准入途径是什么？
Clémentine Body,Frédéric Chassagnol,Driss Berdaï et al.
Clémentine Body et al.
Level V clinical added value (CAV) refers to a lack of CAV improvement of a new medicine, as assessed by the French Transparency Committee, compared to a standard of care therapeutic strategy. In 2024, 56% of medicines evaluated in primary ...
Développer, organiser et valoriser les structures d’évaluation des technologies de santé hospitalières en France [0.03%]
开发、组织和评估法国医院卫生技术结构的价值
Nicolas Martelli,Christophe Roussel,Anne Grumblat et al.
Nicolas Martelli et al.
Dispositif médical à usage professionnel : quelle évaluation, quel financement ? [0.03%]
专业医疗设备：如何评估和融资？
Valéry-Pierre Riche,Laure de Place,Xavier Armoiry et al.
Valéry-Pierre Riche et al.